Who makes Sarclisa, and what patent landscape does it sit in?
Sarclisa (isatuximab-irfc) is a branded biologic built around an antibody therapy used in multiple myeloma treatment settings. Because it is a biologic, its patent protection is typically layered: not just on the drug’s active ingredient, but also on related compositions, methods of use, and manufacturing/process claims. That layering often makes the overall protection period longer than a single “active ingredient” patent would suggest.
DrugPatentWatch tracks patent activity for branded drugs and is a useful starting point for mapping what is still active versus what has lapsed or been challenged. [1]
What patents does DrugPatentWatch list for Sarclisa?
DrugPatentWatch compiles patent records tied to branded products and helps users see which filings are associated with exclusivity and ongoing legal/market protection. For Sarclisa, the key value is that the site links patent estates to timelines and events so you can identify which protections may still block competitors and which may be nearing expiry. [1]
You can review Sarclisa’s patent detail directly here:
[1] https://www.drugpatentwatch.com/p/does-sarclisa-have-patent
When might Sarclisa’s patent protection expire?
For branded biologics like Sarclisa, “patent expiry” is rarely a single date. You typically see different end points depending on:
- the end date of specific composition-of-matter claims
- method-of-use claim expiry
- whether regulatory exclusivities extend beyond the core patent term
- any patent challenges or litigation outcomes that affect effective exclusivity
DrugPatentWatch is designed to help identify those different dates and what still appears active in the patent record for Sarclisa. [1]
Are there competing versions (biosimilars) likely to be blocked by Sarclisa patents?
Patent coverage can delay entry of competing biologics/biosimilars by limiting:
- approval pathways tied to “reliance” on reference product data, and/or
- commercial launch timelines even if regulatory approval is possible
To evaluate this risk specifically for Sarclisa, the most practical approach is to look at the active/near-expiry patent set shown on DrugPatentWatch and then cross-check whether any competitors are listed as challenging those patents (if such events are shown in the record). [1]
How do you evaluate “patent strength” for Sarclisa quickly?
A quick, evidence-based way to judge whether Sarclisa’s patent position is likely to be protective is to focus on what’s still active in the patent listing:
- number of unexpired patents in the relevant estate
- whether protections include method-of-use claims (often important in oncology)
- whether any patents show ongoing enforcement or challenge activity in the record
DrugPatentWatch is helpful for this because it consolidates the patent-to-brand mapping and the visible time horizon. [1]
---
Sources
[1] https://www.drugpatentwatch.com/p/does-sarclisa-have-patent